ProCE Banner Activity

Applying HCV Treatment as Prevention in Germany: Successes and Ongoing Challenges

Clinical Thought
HCV prevalence remains high among PWID and incarcerated individuals in Germany, as barriers to care persist. How can we best provide both HCV treatment and harm reduction services to these key populations? Here’s my take.

Released: May 17, 2019

Expiration: May 15, 2020

No longer available for credit.

Share

Faculty

Heiner Wedemeyer

Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Partners

INHSU

ProCE Banner

Faculty Disclosure

Primary Author

Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Heiner Wedemeyer, MD, has disclosed that he has received consulting fees from Abbott, AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD/Merck, and Roche and funds for research support from Abbott, AbbVie, and Gilead Sciences.